Insulin-like growth factor 1 (IGF-1) is central to aging biology, but its role is paradoxical: the body needs it for tissue repair, yet chronic IGF-1 signaling appears to accelerate aging through chronic inflammation. This paper proposes a 'biphasic senescence switch' model to explain this paradox—the timing and duration of IGF-1 exposure, not just the level, determines whether cells benefit or age. Short bursts of IGF-1 support healthy cell maintenance, while sustained activation locks cells into senescence (a permanent non-dividing state) via increased reactive oxygen species (ROS), DNA damage, and activation of tumor-suppressor pathways (p53/p21). This triggers the senescence-associated secretory phenotype (SASP)—a cascade of pro-inflammatory molecules that spreads aging signals to neighboring cells.
A key player in this process is IGF-binding protein-5 (IGFBP-5), which the authors argue acts as an amplifier of senescence, particularly in blood vessel and connective tissue cells. Critically, new evidence suggests that extracellular vesicles (tiny cell-derived particles) can carry IGF-1 signals and bypass the body's normal regulatory proteins, allowing senescence to spread even when circulating IGF-1 levels are controlled. The authors use two rare human conditions to support their model: Laron syndrome (IGF-1 deficiency, often associated with longer lifespans) and acromegaly (IGF-1 excess, linked to shorter lifespans and disease).
The paper is a narrative review—it synthesizes existing research rather than reporting new experimental data. The authors do not conduct a systematic literature search, meta-analysis, or original experiments. Instead, they synthesize scattered findings into a conceptual framework and propose that precision senomodulation—combining temporal tuning of IGF-1 signaling with senolytic drugs (that kill senescent cells) and senomorphic drugs (that reduce SASP inflammation)—could be a therapeutic strategy. This is intellectually coherent but speculative at this stage.
Limitations are substantial. First, most evidence cited comes from cell culture, animal models, and observational human studies; randomized controlled trials testing this biphasic model in humans are essentially absent. Second, the complexity of IGF-1 signaling varies dramatically across tissues (liver, muscle, brain, immune cells respond differently), yet the review sometimes treats it as a single system. Third, no original data are presented, so claims cannot be directly evaluated for rigor. Fourth, the paper was published very recently (March 2026) with zero citations, making it impossible to assess whether the scientific community finds the framework compelling or flawed. Fifth, the journal *Cytokine* is well-regarded but not a top-tier venue, and this type of narrative review carries inherently lower credibility than empirical studies.
For longevity research, this work is valuable as a thought-provoking synthesis that integrates the IGF-1 paradox into a testable framework. If validated, the biphasic model could guide rational drug design and combination therapies. However, the evidence remains largely correlational and indirect. The proposal to use senolytics + senomorphics alongside IGF-1 modulation is promising but unproven in humans; clinical trials would be needed. The mention of extracellular vesicles as a mechanism of SASP spread is particularly novel and warrants experimental follow-up.
Bottom line: This review articulates an intellectually appealing hypothesis but does not provide new data or definitive evidence. It is best read as a roadmap for future research, not a validated discovery. Clinicians and individuals should not adjust IGF-1 targeting based on this alone; properly controlled human trials are essential before any such interventions are recommended.
0 Comments
Log in to join the discussion.